MA45488A - Procédés, kits et appareil de culture de cellules - Google Patents

Procédés, kits et appareil de culture de cellules

Info

Publication number
MA45488A
MA45488A MA045488A MA45488A MA45488A MA 45488 A MA45488 A MA 45488A MA 045488 A MA045488 A MA 045488A MA 45488 A MA45488 A MA 45488A MA 45488 A MA45488 A MA 45488A
Authority
MA
Morocco
Prior art keywords
kits
cell culture
culture processes
processes
cell
Prior art date
Application number
MA045488A
Other languages
English (en)
Inventor
Keenan Bashour
Lothar Germeroth
Patricia Gräf
Christian Stemberger
Original Assignee
Juno Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA45488A publication Critical patent/MA45488A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/20—Small organic molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
MA045488A 2015-10-22 Procédés, kits et appareil de culture de cellules MA45488A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562245252P 2015-10-22 2015-10-22
US201562245261P 2015-10-22 2015-10-22

Publications (1)

Publication Number Publication Date
MA45488A true MA45488A (fr) 2018-08-29

Family

ID=57394616

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045488A MA45488A (fr) 2015-10-22 Procédés, kits et appareil de culture de cellules

Country Status (17)

Country Link
US (2) US11466253B2 (fr)
EP (1) EP3365434A1 (fr)
JP (3) JP6895959B2 (fr)
KR (1) KR20180100110A (fr)
CN (2) CN117106716A (fr)
AU (1) AU2016341529B2 (fr)
BR (1) BR112018008081A2 (fr)
CA (1) CA3002745A1 (fr)
HK (1) HK1258931A1 (fr)
IL (2) IL307934A (fr)
MA (1) MA45488A (fr)
MX (3) MX2018004874A (fr)
NZ (1) NZ741878A (fr)
PH (1) PH12018500860A1 (fr)
RU (1) RU2761557C2 (fr)
SG (1) SG11201803330WA (fr)
WO (1) WO2017068421A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263375B2 (en) 2002-12-20 2012-09-11 Acea Biosciences Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
US10551371B2 (en) 2003-11-10 2020-02-04 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function
US11346797B2 (en) 2002-12-20 2022-05-31 Agilent Technologies, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties
US10539523B2 (en) 2002-12-20 2020-01-21 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties
US10215748B2 (en) 2002-12-20 2019-02-26 Acea Biosciences, Inc. Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways
EP1692258A4 (fr) 2003-11-12 2007-03-21 Xiao Xu Systemes de detection de cellules electroniques en temps reel pour des epreuves a base de cellules
CA2723223C (fr) 2008-05-05 2017-06-06 Acea Biosciences, Inc. Surveillance sans marqueur d'un couplage excitation-contraction et cellules pouvant etre excitees utilisant des systemes fondes sur l'impedance avec une resolution dans le temps de l'ordre de la milliseconde
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
PL3132247T3 (pl) 2014-04-16 2022-01-03 Juno Therapeutics Gmbh Sposoby, zestawy i urządzenie do namnażania populacji komórek
CN116875635A (zh) 2015-10-22 2023-10-13 朱诺治疗学有限公司 用于转导的方法、反应剂盒、反应剂和设备
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CN110199016A (zh) 2016-11-17 2019-09-03 艾欧凡斯生物治疗公司 残余肿瘤浸润淋巴细胞及其制备和使用方法
US11357841B2 (en) 2017-01-06 2022-06-14 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
WO2018161063A1 (fr) 2017-03-03 2018-09-07 Acea Biosciences, Inc. Procédés et systèmes pour la maturation fonctionnelle de cardiomyocytes dérivés de cspi et de cellule se
WO2018170288A1 (fr) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Immunotolérance ciblée
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
BR112019022356A2 (pt) 2017-04-27 2020-05-26 Juno Therapeutics Gmbh Reagentes de partícula oligoméricos e métodos de uso dos mesmos
BR112019024127A2 (pt) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. Imunotolerância alvejada
CN110770348B (zh) 2017-06-01 2023-12-15 浙江煦顼技术有限公司 嵌合抗原受体细胞的制备及其用途
US11235004B2 (en) 2017-06-30 2022-02-01 Innovative Cellular Therapeutics Holdings, Ltd. Lymphocyte cell lines and uses thereof
US20210364494A1 (en) * 2017-08-01 2021-11-25 Acea Biosciences, Inc. Cell-substrate impedance monitoring of cancer cells of different lineage, origin, or stage
ES2959953T3 (es) 2017-08-09 2024-02-29 Juno Therapeutics Inc Métodos para producir composiciones celulares genéticamente modificadas y composiciones relacionadas
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019241426A1 (fr) 2018-06-13 2019-12-19 Novartis Ag Récepteurs d'antigènes chimériques bcma et leurs utilisations
BR122021012517A2 (pt) 2018-08-06 2021-08-10 Medikine, Inc. Ligante il-2rgamac, composto compreendendo referido ligante, composição farmacêutica e uso do referido ligante
US20210163893A1 (en) * 2018-08-09 2021-06-03 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
JP2021534785A (ja) * 2018-08-28 2021-12-16 フレッド ハッチンソン キャンサー リサーチ センター 誘導ノッチシグナル伝達を用いた養子ｔ細胞療法の方法及び組成物
EP3844267A2 (fr) * 2018-08-31 2021-07-07 Novartis AG Procédés de fabrication de cellules exprimant un récepteur d'antigène chimère
BR112021008133A2 (pt) * 2018-10-31 2021-10-05 Juno Therapeutics Gmbh Métodos para seleção e estimulação de células e aparelhos para os mesmos
MX2021005372A (es) 2018-11-08 2021-09-14 Neximmune Inc Composiciones de linfocitos t con propiedades fenotípicas mejoradas.
US20220064598A1 (en) * 2019-01-07 2022-03-03 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
KR20200132147A (ko) * 2019-05-15 2020-11-25 의료법인 성광의료재단 자연 살해 세포의 배양용 조성물 및 이를 이용한 방법
KR20220035333A (ko) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 Madcam 표적 면역관용
BR112022008023A2 (pt) 2019-10-30 2022-07-12 Juno Therapeutics Gmbh Dispositivos de seleção e/ou estimulação de células e métodos de uso
BR112022008744A2 (pt) 2019-11-05 2022-07-19 Medikine Inc Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
MX2022005998A (es) * 2019-11-20 2022-06-17 Gi Cell Inc Composicion para el cultivo de linfocitos t asesinos naturales y metodo para la preparacion de linfocitos t asesinos naturales mediante el uso de la misma.
WO2021101271A1 (fr) * 2019-11-20 2021-05-27 주식회사 지아이셀 Composition de milieu pour la culture de lymphocytes t et procédé pour la culture de lymphocytes t l'utilisant
JP2023503161A (ja) 2019-11-26 2023-01-26 ノバルティス アーゲー Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
KR102400253B1 (ko) * 2019-11-27 2022-05-23 ㈜지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 면역관문 억제제를 포함하는 암 치료용 약학 조성물
CN115003818A (zh) * 2020-01-22 2022-09-02 科济生物医药（上海）有限公司 病毒载体转导细胞的方法
KR20220139918A (ko) 2020-02-03 2022-10-17 메디카인 인코포레이티드 IL-7Rαγc 결합 화합물
WO2022098787A1 (fr) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cellules exprimant un récepteur chimérique à partir d'un locus de chaîne de la superfamille des immunoglobines cd3 invariable modifié, polynucléotides et procédés associés
CN113125718A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的45抗体试剂盒及应用
CN113125733A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的42抗体试剂盒及应用
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
WO2023213969A1 (fr) * 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Protéine de liaison virale et réactifs, articles et méthodes d'utilisation associés

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
DE3583940D1 (de) 1984-10-02 1991-10-02 Harry M Meade Herstellung von streptavidinaehnlichen polypeptiden.
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
DE68919715T2 (de) 1988-12-28 1995-04-06 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
EP0557459B1 (fr) 1990-11-13 1997-10-22 Immunex Corporation Genes de fusion selectionnables bifonctionnels
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
EP0804590A1 (fr) 1993-05-21 1997-11-05 Targeted Genetics Corporation Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd)
ATE293686T1 (de) 1993-06-04 2005-05-15 Us Navy Verfahren zur selektiven stimulierung der t- zellproliferation.
EP0638644A1 (fr) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Récepteurs de l'interleukine 12 et anticorps
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5853721A (en) 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
WO1996024606A1 (fr) 1995-02-09 1996-08-15 University Of Washington Streptavidine a affinite modifiee
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
CA2222035A1 (fr) 1995-04-11 1997-03-27 Trustees Of Boston University Proteines mutantes de streptavidine
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998040396A1 (fr) 1997-03-14 1998-09-17 Trustees Of Boston University Streptavidine a aromes multiples
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
US6153441A (en) 1998-02-17 2000-11-28 Smithkline Beecham Corporation Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
AU765822B2 (en) 1998-05-23 2003-10-02 Leiden University Medical Center CD40 binding molecules and CTL peptides for treating tumors
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
NZ513303A (en) 1999-02-04 2003-03-28 Technion Res & Dev Foundation Three dimensional plug flow bioreactor, and its use for the maintenance and expansion of hemopoietic stem cells and/or progenitor cells
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
WO2001056603A1 (fr) 2000-02-01 2001-08-09 Tanox, Inc. Molecules d'activation des apc se liant au cd40
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
CA2410510A1 (fr) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
WO2002022805A2 (fr) 2000-09-14 2002-03-21 Beth Israel Deaconess Medical Center, Inc. Modulation de reactions de cellules t induites par il-15 et il-2
JP5312721B2 (ja) 2000-11-07 2013-10-09 シティ・オブ・ホープ Ｃｄ１９特異的再指向免疫細胞
EP1227321A1 (fr) * 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Purification fonctionelle de lymphocytes T antigène-spécifiques par marquage réversible aux multimères MHC
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
EP2009027B1 (fr) 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-CD40
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030077247A1 (en) 2001-09-20 2003-04-24 Schering Corporation Chemokines as adjuvants of immune response
WO2003029462A1 (fr) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees
AU2003222717A1 (en) 2002-03-01 2003-09-16 Erdmann, Volker, A. Streptavidin-binding peptide
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7754155B2 (en) 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
EP1507557A4 (fr) 2002-04-23 2006-06-14 Meir Strahilevitz Procedes et dispositifs permettant de cibler un site chez un mammifere et d'oter des especes chimiques d'un mammifere
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2007001459A2 (fr) 2004-11-15 2007-01-04 Washington University Compositions et procedes pour moduler l'activite lymphocytaire
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
EP2351770A1 (fr) 2002-07-17 2011-08-03 Cytos Biotechnology AG Matrice moléculaire d'antigènes utilisant une particule virale de type AP205
EP1447093A1 (fr) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition du système de CD95 ligand/récepteur pour le traitement des troubles et des dommages neurologiques
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
KR20060015482A (ko) 2003-03-21 2006-02-17 와이어쓰 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
MXPA05012080A (es) 2003-05-08 2006-02-22 Xcyte Therapies Inc Generacion y aislamiento de celulas t especificas al antigeno.
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
AU2004290017B2 (en) 2003-11-07 2012-05-03 Immunex Corporation Antibodies that bind interleukin-4 receptor
JP2007512528A (ja) 2003-11-20 2007-05-17 バイオセンサー、アプリケーションズ、スエーデン、アクチボラグ 所定の抗原混合物に特異的な少なくとも２種類の異なる抗体の混合物およびその混合物の使用
CA2546054C (fr) 2003-12-10 2014-05-13 Medarex, Inc. Anticorps contre l'interferon alpha et leur utilisations
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
ES2586295T3 (es) 2004-02-26 2016-10-13 Immunovative Therapies, Ltd. Malcha Technology Park Los métodos para preparar las células T para la terapia celular
EP1766400B1 (fr) 2004-06-03 2009-04-15 Meso Scale Technologies, LLC Methodes destinees a realiser des analyses de sang total
CA2570823C (fr) 2004-06-21 2015-02-24 Medarex, Inc. Anticorps anti-recepteur aux interferons alpha 1 et leurs utilisations
CA2572334A1 (fr) 2004-07-01 2006-01-19 New York University Compositions et procedes pour la modulation du ror.gamma.t
JP2008508885A (ja) 2004-08-05 2008-03-27 ワイス インターロイキン−２１受容体活性を中和すること
US20110098184A1 (en) 2004-10-15 2011-04-28 Day Anthony G Competitve differntial screeing
AU2004325035B2 (en) 2004-11-12 2011-09-08 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2006058226A2 (fr) 2004-11-24 2006-06-01 The Trustees Of Boston University Streptavidines dimeres modifiees et leurs utilisations
US20060252087A1 (en) 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
US7553932B1 (en) 2005-04-25 2009-06-30 La Jolla Institute For Allergy And Immunology Methods of treating viral infection with IL-10 receptor antagonists
KR20080047564A (ko) 2005-09-28 2008-05-29 사이토스 바이오테크놀로지 아게 인터루킨-1 컨쥬게이트 및 그의 용도
US20100068192A1 (en) * 2005-09-30 2010-03-18 Takara Bio Inc. Method for Production of T Cell Population
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US7704708B2 (en) 2006-02-13 2010-04-27 Uti Limited Partnership Monomeric streptavidin muteins
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2008047473A1 (fr) 2006-10-17 2008-04-24 Oncotherapy Science, Inc. Vaccins peptidiques pour des cancers exprimant les polypeptides mphosph1 ou depdc1
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CN105699662A (zh) 2006-11-02 2016-06-22 协和梅迪克斯株式会社 免疫测定待测组分的方法
EP2518193A3 (fr) 2006-11-15 2013-01-23 Invitrogen Dynal AS Procedes pour lier de facon reversible un compose de Biotine a un support
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US9309320B2 (en) 2006-12-28 2016-04-12 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
CN101226118B (zh) 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
KR20080076622A (ko) 2007-02-16 2008-08-20 포항공과대학교 산학협력단 올리고머화된 단백질 전달체와 이를 이용한 세포내바이러스 벡터 전달 방법
JP5754135B2 (ja) 2007-03-26 2015-07-29 アジェナス インコーポレイテッド 関心対象のタンパク質の細胞表面ディスプレイ、スクリーニング、および産生
AU2008233051B2 (en) 2007-03-30 2014-04-10 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
RU2549701C2 (ru) 2007-05-07 2015-04-27 Медиммун, Ллк Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний
PL2193199T3 (pl) 2007-08-20 2014-04-30 Nextera As Ekspozycja fagowa pVII
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
AU2009205956B2 (en) 2008-01-18 2015-07-02 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
ES2666667T3 (es) 2008-01-29 2018-05-07 Fred Hutchinson Cancer Research Center Identificación de células T CD8+ que son CD161 hi y/o IL-18R (alfa) hi y tienen una capacidad de evacuación rápida de fármacos
CN106986926A (zh) 2008-01-30 2017-07-28 皮里斯股份公司 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
WO2009145831A1 (fr) 2008-04-02 2009-12-03 Geisinger Clinic Traitement des maladies à spectre de syndrome néphrotique idiopathique à l'aide de basiliximab
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
CA2729567C (fr) 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-cd27
US8775327B2 (en) 2008-07-03 2014-07-08 Oracle International Corporation Combined directory of personal and enterprise application system data
CA2730909A1 (fr) 2008-08-28 2010-03-04 Abbott Biotherapeutics Corp. Procede de traitement de patients souffrant de sclerose en plaques avec des anticorps anti-il2r
CN101446576B (zh) 2008-12-29 2011-06-22 江苏省苏微微生物研究有限公司 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法
WO2010080032A2 (fr) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Transduction virale assistée par des billes
EP2419121B1 (fr) 2009-04-17 2018-07-18 New York University Peptides ciblant les récepteurs de la famille du tnf et contrant l'action du tnf, compositions, méthodes et utilisations afférentes
WO2010126890A1 (fr) 2009-04-27 2010-11-04 Facet Biotech Corporation Procédés de surveillance de l'efficacité d'anticorps anti-il-2r chez des patients atteints de sclérose en plaques
EP2473851A1 (fr) 2009-08-31 2012-07-11 Abbott Biotherapeutics Corp. Utilisation d'une population de cellules nk immunorégulatrices pour surveiller l'efficacité d'anticorps anti-il-2r chez des patients atteints d'une sclérose en plaques
WO2011053971A2 (fr) 2009-11-02 2011-05-05 Fina Biosolutions, Llc Procédé d'amélioration de sensibilité d'analyses à base d'anticorps
US20120321665A1 (en) 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
EP2363501A1 (fr) 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Nanocomposites dotés d'une homogénéité améliorée
BR112012026227A2 (pt) 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo
EP2601521B1 (fr) 2010-08-06 2018-05-02 Ludwig-Maximilians-Universität München Identification d'antigènes cibles de lymphocytes t
WO2012058627A2 (fr) 2010-10-29 2012-05-03 Miqin Zhang Système de nanoparticules préciblées et procédé de marquage de particules biologiques
KR102062407B1 (ko) 2010-12-09 2020-01-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
CA2824278C (fr) 2010-12-20 2022-09-20 The Rockefeller University Modulation d'anticorps agonistes anti-tnfr
BR112013024395B1 (pt) 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center Composições adotivas de imunoterapia celular e método para fabricação da dita composição
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
PT2734538T (pt) * 2011-07-18 2018-08-02 Iba Gmbh Processo para corar, de forma reversível, uma célula-alvo
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
BR112014011417B1 (pt) 2011-11-11 2021-10-13 Fred Hutchinson Cancer Research Center Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
ES2774160T3 (es) 2012-02-13 2020-07-17 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
BR122020002414B1 (pt) 2012-03-15 2022-03-03 Janssen Biotech, Inc Uso de anticorpos anti-cd27 humanos
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
AU2013305838A1 (en) 2012-08-20 2015-02-26 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
WO2014039044A1 (fr) 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de production de populations de cellules souches t mémoires
EP2711418B1 (fr) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Procédé de stimulation polyclonales de lymphocyte T par nanomatrices flexibles
WO2014055668A1 (fr) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions et procédés d'immunothérapie
US10065996B2 (en) 2012-11-16 2018-09-04 Iba Gmbh Streptavidin muteins and methods of using them
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
JP2016531907A (ja) 2013-08-02 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
MY178233A (en) 2013-12-20 2020-10-07 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
EP3632934A1 (fr) 2014-03-31 2020-04-08 F. Hoffmann-La Roche AG Anticorps anti-ox40 et procédés d'utilisation
WO2015153514A1 (fr) 2014-03-31 2015-10-08 Genentech, Inc. Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
PL3132247T3 (pl) * 2014-04-16 2022-01-03 Juno Therapeutics Gmbh Sposoby, zestawy i urządzenie do namnażania populacji komórek
CN113046312A (zh) 2014-04-23 2021-06-29 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
JP6661544B2 (ja) 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
JP6678593B2 (ja) 2014-04-30 2020-04-08 イーベーアー ゲーエムベーハー 標的細胞を単離する方法
EP2955196A1 (fr) 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
EP3161003A2 (fr) 2014-06-27 2017-05-03 Apogenix GmbH Combinaison d'inhibition du cd95/cd95l et d'immunothérapie du cancer
RU2017111228A (ru) 2014-10-18 2018-11-21 Пфайзер Инк. Композиции антитела против IL-7R
WO2016166568A1 (fr) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Procédés, kits et appareil permettant d'augmenter une population de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
CN116875635A (zh) 2015-10-22 2023-10-13 朱诺治疗学有限公司 用于转导的方法、反应剂盒、反应剂和设备
AU2016363025B2 (en) 2015-12-03 2021-04-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
CN110418802A (zh) 2017-01-20 2019-11-05 朱诺治疗学有限公司 细胞表面缀合物及相关的细胞组合物和方法
BR112019022356A2 (pt) 2017-04-27 2020-05-26 Juno Therapeutics Gmbh Reagentes de partícula oligoméricos e métodos de uso dos mesmos
US20210163893A1 (en) 2018-08-09 2021-06-03 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
BR112021008133A2 (pt) 2018-10-31 2021-10-05 Juno Therapeutics Gmbh Métodos para seleção e estimulação de células e aparelhos para os mesmos

Also Published As

Publication number Publication date
AU2016341529B2 (en) 2023-03-30
JP2018531035A (ja) 2018-10-25
IL307934A (en) 2023-12-01
MX2022012147A (es) 2023-03-01
PH12018500860A1 (en) 2018-11-05
EP3365434A1 (fr) 2018-08-29
CN117106716A (zh) 2023-11-24
RU2018118575A (ru) 2019-11-27
HK1258931A1 (zh) 2019-11-22
SG11201803330WA (en) 2018-05-30
BR112018008081A2 (pt) 2018-11-13
WO2017068421A1 (fr) 2017-04-27
CN108431210B (zh) 2023-05-23
MX2022012148A (es) 2023-03-01
JP2021137025A (ja) 2021-09-16
CN108431210A (zh) 2018-08-21
RU2018118575A3 (fr) 2020-07-28
KR20180100110A (ko) 2018-09-07
US20230295567A1 (en) 2023-09-21
AU2016341529A1 (en) 2018-05-10
MX2018004874A (es) 2018-12-12
NZ741878A (en) 2024-03-22
US11466253B2 (en) 2022-10-11
JP2023138707A (ja) 2023-10-02
JP6895959B2 (ja) 2021-06-30
IL258844B2 (en) 2024-03-01
RU2761557C2 (ru) 2021-12-09
US20190136186A1 (en) 2019-05-09
IL258844B1 (en) 2023-11-01
IL258844A (en) 2018-06-28
JP7390334B2 (ja) 2023-12-01
CA3002745A1 (fr) 2017-04-27

Similar Documents

Publication Publication Date Title
MA45488A (fr) Procédés, kits et appareil de culture de cellules
IL284235A (en) Kits and methods for preparing a microfluidic device for cell culture
HK1258933A1 (zh) 培養細胞的方法及用於該方法的試劑盒和設備
IL280738A (en) Methods, kits and device for increasing cell populations
HK1253095A1 (zh) 細胞培養裝置、系統及其使用方法
LU92752B1 (en) Cell culture apparatus and culture methods using same
MA45426A (fr) Procédés, kits, agents et appareils de transduction
EP3472301C0 (fr) Dispositif et procédés de culture cellulaire
DK3215601T3 (da) Fremgangsmåder til transduktion og celleforarbejdning
DK3279310T3 (da) Celledyrkningsapparat og fremgangsmåde til celledyrkning
LT3263715T (lt) Pavienių ląstelių transkriptomo analizės būdas
SG11201705866XA (en) Method, device and kit for mass cultivation of cells using polyimide porous membrane
ES2966757T3 (es) Métodos de reprogramación mejorados y plataformas de cultivo celular
SG11201609916RA (en) Culture method and cell mass
EP3196292A4 (fr) Dispositif et procédé de culture cellulaire
DK3766582T3 (da) Cellekultur
EP3330367A4 (fr) Appareil d'analyse de cellules utilisant une pluralité de lasers
EP3235900A4 (fr) Appareil de culture cellulaire
IL261999A (en) Cell culture process
GB2587768B (en) Devices and methods for purification, detection and use of biological cells
GB201608899D0 (en) Skin sample culture apparatus
EP3260528A4 (fr) Appareil de culture cellulaire
EP3101421A4 (fr) Dispositif d'observation et d'analyse de membrane cellulaire et procédé d'observation et d'analyse de membrane cellulaire
TH176299B (th) วิธีการบำบัดทางชีวภาพและชุดเครื่องบำบัดทางชีวภาพ
EP3202888A4 (fr) Dispositif et procédé d'observation de culture cellulaire